1185P - Prognostic Role of ERBB Family Receptors, MYC and Mitogen-Activated Protein Kinase (MAPK) in Patients with Early-Stage non Small-Cell Lung Cancer

Abstract

ABSTRACT Background EGFR deregulation has been extensively studied in non small-cell lung cancer (NSCLC), but the expression and the role of other ErbB receptors and their downstream signal transductions remains still unclear. MYC and MAPK are key downstream components of the EGFR pathway and have significant roles in cell survival, proliferation, and growth. This study evaluates the prognostic role of EGFR, ErbB2, ErbB3, ErbB4, MYC and MAPK by immunohistochemistry (IHC) in early stage NSCLC. Methods One-hundred nine NSCLC patients were evaluated: median age was 67 years (range 40–84); Male/Female: 93/16; squamous (SCC)/adenocarcinoma (ADC)/BAC/other: 52/36/3/18; smoker/never smoker:100/9, and stage I/II/III:67/17/25. IHC results were evaluated by two independent observers and the tumors with ≥10% positive cells were classified positive, further confirmed by Receiver Operating Characteristic (ROC) analysis. Kaplan-Meier estimates of survival and time to recurrence were calculated for clinical and biologic variables using Cox model for multivariate analysis. Results EGFR was expressed in 55.9%, ErbB2 in 24.7% ErbB3 in 33.9%, ErbB4 in 27.5%, Myc in 23.8% and MAPK in 27.5 % of patients, respectively. EGFR and ErbB3 were associated with SCC (p Conclusions Our results suggest that in early stage NSCLC the co-expression of EGFR, ErbB2 and MAPK predicted a worse prognosis. Such features may have important implications for future targeted therapies. We thank Italian Association for Cancer Research (AIRC) for supporting the study. Disclosure All authors have declared no conflicts of interest.